Protalex, Inc. Announces Data from U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients Presented At The 2014 EULAR Annual European Congress of Rheumatology

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR’s Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR’s website at www.eular.org and the complete poster is available on the Company’s website at www.protalex.com.

Help employers find you! Check out all the jobs and post your resume.